TABLE 6.

Everolimus strategies.

Demographics	CNI minimization (n = 55)	CNI elimination (n = 36)	p-value
Characteristic
Age (yr), mean	51.47 ± 14.10	51.89 ± 13.75	0.89
Gender: male, n (%)	25 (45.4)	24 (66.7)	0.047
Indication for transplantation, n (%)
Chronic obstructive pulmonary disease	24 (43.6)	19 (52.8)	0.305
Cystic fibrosis	12 (21.8)	7 (19.4)	0.785
Interstitial lung disease	12 (21.8)	7 (19.4)	0.785
Pulmonary hypertension	4 (7.3)	2 (5.6)	0.747
Other	3 (5.5)	1 (2.8)	0.416
Transplantation type, n (%)
Bilateral sequential lung	49 (89.0)	32 (88.9)	0.83
Single lung	5 (9.2)	4 (11.1)	0.75
Heart and lung	1 (1.8)	0 (0.0)	1.00
Maintenance Immunosuppression, n (%)#
Tacrolimus	47 (85.5)	26 (72.2)	0.12
Ciclosporin	8 (14.5)	6 (16.7)	0.78
Mycophenolate	19 (34.5)	19 (52.8)	0.09
Azathioprine	25 (45.5)	9 (25.0)	0.049
Rejection
ISHLT graded ≥2 ACR^	8 (14.5)	5 (13.9)	0.93
Diagnosis of CLAD*	34 (61.8)	23 (63.9)	0.72
RAS	18 (32.7)	13 (23.6)	0.48
BOS	16 (29.1)	10 (18.2)	0.63

Abbreviations: ACR, acute cellular rejection; BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; CNI, calcineurin inhibitor; EVE, everolimus; RAS, restrictive allograft syndrome.

^#Maintenance immunosuppression at time of switch to EVE.

^Episode of ISHLT graded ≥ 2 ACR pre or post switch to EVE.

*Diagnosis of BOS or rCLAD pre or post switch to EVE.